The Financial Times writes it, anticipating the results of the ongoing phase 3 clinical trial. Our country among the first to benefit from the vaccine
According to the newspaper, the vaccine stimulates the production of protective antibodies and T lymphocytes, a necessary but not sufficient condition to establish efficacy and which does not provide safety information. The immune response is similar to that already observed in adults between 18 and 55 years old, already described in July.
These results too, the Financial Times reports, will soon be published in a scientific journal. Testing of the vaccine in the US has just resumed, after a stoppage for analysis of some side effects reported by the company.
Italy among the first to have the Oxford vaccine – Of the first 20-30 million doses of the Covid vaccine developed by the University of Oxford, 2-3 million should reach Italy. This was stated by Piero Di Lorenzo, president of Irbm di Pomezia, an Italian company that is contributing to development. “The Minister of Health, Roberto Speranza, has done a miracle by being able to fit into the leading group of European countries that have reserved the vaccine, and therefore Italy is in an advantageous condition,” he said. Of those 20-. 30 million doses I was talking about, 2 or 3 million will reach our country immediately ”.
